Modulatory effects of eicosanoids on mesangial cell growth in response to immune injury.
In a rat model of glomerular mesangial cell immune injury induced by a monoclonal antibody (ER4) against the mesangial cell membrane antigen Thy 1.1 and in which mesangial cell proliferation is a prominent feature, we examined the role of arachidonate 5- and 12-lipoxygenation (LO) eicosanoids and of thromboxane (Tx) in modulating the proliferative response. Significant increments in glomerular cell proliferation, assessed by counting glomerular cells positive for the Proliferating Cell Nuclear Antigen (PCNA) and by the incorporation of [3H]thymidine ([3H]TdR) in mesangial cell outgrowths from explanted glomeruli, occurred during the mesangioproliferative phase of injury. This event was abrogated in animals depleted of leukocytes or platelets prior to administration of ER4 and in animals pretreated with the arachidonate 5-LO inhibitor MK886. Pretreatment with the Tx synthase inhibitor, Furegrelate, or the arachidonate 12-LO inhibitor, Baicalein, had no effect, indicating that eicosanoids of arachidonate 5-LO but not those of 12-LO or Tx modulate mesangial cell proliferation following immune injury. We further identified those 5-lipoxygenation eicosanoids with growth modulatory effects on cultured mesangial cells. Leukotriene (LT)C4 and D4 but not LTB4 or 5-hydroxyeicosatetraenoic (HETE) acid enhanced [3H]TdR incorporation in growth-arrested mesangial cells. This effect of LTC4 and LTD4 was abrogated by the specific protein kinase C (PKC) inhibitor calphostin C, indicating a PKC-dependent mechanism. LTC4 and LTD4 but not 5-HETE or LTB4 also increased mesangial cell mass levels of the endogenous PKC activator diacylglycerol. The observations indicate that leukocyte-derived arachidonate 5-LO eicosanoids modulate mesangial cell proliferation following immune injury. Of these LTC4 and LTD4 are the likely candidates as they promote mesangial cell growth via a PKC-dependent mechanisms.
Wu
S H
SH
Department of Medicine, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee.
Kelefiotis
D P
DP
Lianos
E A
EA
D000818:Animals; D000911:Antibodies, Monoclonal; D001091:Arachidonate Lipoxygenases / Q000037:antagonists & inhibitors / Q000378:metabolism; D002455:Cell Division / Q000276:immunology / Q000502:physiology; D015777:Eicosanoids / Q000502:physiology*; D005260:Female; D005920:Glomerular Mesangium / Q000166:cytology* / Q000276:immunology*; D015289:Leukotrienes / Q000502:physiology; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D011493:Protein Kinase C / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew; D013931:Thromboxanes / Q000502:physiology; D018800:Thy-1 Antigens / Q000276:immunology
D000911:Antibodies, Monoclonal; D015777:Eicosanoids; D015289:Leukotrienes; D018809:Proliferating Cell Nuclear Antigen; D013931:Thromboxanes; D018800:Thy-1 Antigens; D001091:Arachidonate Lipoxygenases; D011493:Protein Kinase C